Evaluation of the Efficacy, Safety and Tolerability of Orally Administered BI 409306, a Novel Phosphodiesterase Type 9 Inhibitor, in Two Randomised Controlled Phase II Studies in Patients With Prodromal and Mild Alzheimer’s Disease

Alzheimer's Research and Therapy - United Kingdom

doi 10.1186/s13195-019-0467-2